Evidence map›Paper›PMID 33148797›Full record

ArticleJournal of virology2021

Identification of an Antiretroviral Small Molecule That Appears To Be a Host-Targeting Inhibitor of HIV-1 Assembly.

Jonathan C Reed, Dennis Solas, Anatoliy Kitaygorodskyy, Beverly Freeman, Dylan T B Ressler, Daryl J Phuong, J Victor Swain, Kent Matlack, Clarence R Hurt, Vishwanath R Lingappa and 1 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of virology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 1 institution in 1 country.

Jonathan C ReedDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Dennis SolasProsetta Biosciences, San Francisco, California, USA.
Anatoliy KitaygorodskyyProsetta Biosciences, San Francisco, California, USA.
Beverly FreemanProsetta Biosciences, San Francisco, California, USA.
Dylan T B ResslerDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Daryl J PhuongDepartment of Global Health, University of Washington, Seattle, Washington, USA.
J Victor SwainDepartment of Global Health, University of Washington, Seattle, Washington, USA.
Kent MatlackProsetta Biosciences, San Francisco, California, USA.
Clarence R HurtProsetta Biosciences, San Francisco, California, USA.
Vishwanath R LingappaProsetta Biosciences, San Francisco, California, USA.
Jaisri R LingappaDepartment of Global Health, University of Washington, Seattle, Washington, USA jais@uw.edu.ORCID 0000-0002-7533-6276
University of Washington · US

Funding

Understanding potent and novel small molecules that target HIV assemblyR21AI154963 · NIAID · UNIVERSITY OF WASHINGTON · PI LINGAPPA, JAISRI R · 2020 to 2021
$485k
Interrogating complexes involved in HIV-1 assembly with biochemistry, imaging, and a small moleculeR56AI145498 · NIAID · UNIVERSITY OF WASHINGTON · PI LINGAPPA, JAISRI R · 2019 to 2019
$441k
HIV packaging occurs in RNA granules: implications for cell biology and anti-retroviral drugsR01AI150457 · NIAID · UNIVERSITY OF WASHINGTON · PI LINGAPPA, JAISRI R · 2019 to 2019
$349k
NIAID NIH HHS R01 AI150457NIAID NIH HHS R21 AI154963NIAID NIH HHS R56 AI145498
6 · The paper itself

Abstract

Given the projected increase in multidrug-resistant HIV-1, there is an urgent need for development of antiretrovirals that act on virus life cycle stages not targeted by drugs currently in use. Host-targeting compounds are of particular interest because they can offer a high barrier to resistance. Here, we report identification of two related small molecules that inhibit HIV-1 late events, a part of the HIV-1 life cycle for which potent and specific inhibitors are lacking. This chemotype was discovered using cell-free protein synthesis and assembly systems that recapitulate intracellular host-catalyzed viral capsid assembly pathways. These compounds inhibit replication of HIV-1 in human T cell lines and peripheral blood mononuclear cells, and are effective against a primary isolate. They reduce virus production, likely by inhibiting a posttranslational step in HIV-1 Gag assembly. Notably, the compound colocalizes with HIV-1 Gag

Indexed as

Anti-Retroviral AgentsATP-Binding Cassette TransportersDEAD-box RNA Helicasesgag Gene Products, Human Immunodeficiency VirusHIV-1HIV InfectionsHumansLeukocytes, MononuclearProto-Oncogene ProteinsSmall Molecule LibrariesVirus AssemblyABCE1 protein, humanAnti-Retroviral AgentsATP-Binding Cassette TransportersDDX6 protein, humanDEAD-box RNA Helicasesgag Gene Products, Human Immunodeficiency VirusProto-Oncogene ProteinsSmall Molecule LibrariesABCE1antiretroviral agentcell-free systemDDX6drug screenHIV-1 assemblyHIV-1 capsidRNA granulesvirus-host interactions

Identifiers

PMID33148797
PMCPMC7925099
OpenAlexW3094905611

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.